INTC
Intel Corporation
INTC lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
SURG
SurgePays, Inc.
There isn't enough reported data to score SURG yet.
INTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Healthy |
INTC's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
SURG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
SURG's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
INTC PE Valuation
INTC has no meaningful PE right now: it lost money over the past year.
SURG PE Valuation
SURG has no meaningful PE right now: it lost money over the past year.
INTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Broad | |
| Low |
INTC has the edge over SURG on the outlook, with more favorable revenue expectations.
SURG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SURG's losses to shrink, with revenue holding steady.
INTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.41 | — |
| Q3 2026 | -$2.39 | -24000% |
| Q2 2026 | -$2.09 | +$2.68 |
| Q1 2026 | -$0.60 | +$3.88 |
| Q4 2025 | -$0.06 | +$4.32 |
| Q3 2025 | $0.01 | +$3.72 |
| Q2 2025 | -$4.77 | -2088% |
| Q1 2025 | -$4.48 | -562% |
| Q4 2024 | -$4.38 | -1195% |
INTC has the edge over SURG on earnings, with more consistent year-over-year improvement.
SURG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$1.02 |
| Q1 2026 | -$1.93 | +$0.91 |
| Q4 2025 | -$1.80 | +$0.59 |
| Q3 2025 | -$2.19 | -$1.05 |
| Q2 2025 | -$2.54 | -3275% |
| Q1 2025 | -$2.84 | -349% |
| Q4 2024 | -$2.39 | -273% |
| Q3 2024 | -$1.14 | -179% |
SURG is still losing money, but far less than before: $1.52 per share over the past year, against $5.50 at its worst in early 2021.
INTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.5B | +21% |
| Q2 2026 | $16.1B | +25% |
| Q1 2026 | $13.6B | +7.2% |
| Q4 2025 | $13.7B | -4.1% |
| Q3 2025 | $13.7B | +2.8% |
| Q2 2025 | $12.9B | +0.2% |
| Q1 2025 | $12.7B | -0.4% |
| Q4 2024 | $14.3B | -7.4% |
INTC's revenue is recovering but still below its 2021 peak: $16.5B last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +10 points |
| Q2 2026 | 11% | +36 points |
| Q1 2026 | -23% | -21 points |
| Q4 2025 | 4.2% | +1.4 points |
| Q3 2025 | 5% | +73 points |
| Q2 2025 | -25% | -9.4 points |
| Q1 2025 | -2.4% | +6 points |
| Q4 2024 | 2.9% | -14 points |
INTC's operating margin was 15% last quarter, up 10 points from the same quarter a year ago.
SURG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.2M | +41% |
| Q1 2026 | $16M | +51% |
| Q4 2025 | $16.2M | +69% |
| Q3 2025 | $18.7M | +292% |
| Q2 2025 | $11.5M | -24% |
| Q1 2025 | $10.6M | -66% |
| Q4 2024 | $9.6M | -70% |
| Q3 2024 | $4.8M | -86% |
SURG's revenue is recovering but still below its 2022 peak: $16M last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | +80 points |
| Q1 2026 | -70% | +1.6 points |
| Q4 2025 | -79% | +113 points |
| Q3 2025 | -37% | +262 points |
| Q2 2025 | -59% | +13 points |
| Q1 2025 | -72% | -77 points |
| Q4 2024 | -192% | -194 points |
| Q3 2024 | -299% | -320 points |
SURG has the edge over INTC on profitability, with a higher operating margin.
INTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +774% |
| Q2 2026 | $4.5B | +$6B |
| Q1 2026 | -$2.5B | +$1.8B |
| Q4 2025 | $800M | +$3.5B |
| Q3 2025 | $121M | +$2.5B |
| Q2 2025 | -$1.5B | +$1.9B |
| Q1 2025 | -$4.4B | +$2.8B |
| Q4 2024 | -$2.7B | -$597M |
INTC has the stronger cash trend. Its trailing FCF is up 258% versus its history, compared with SURG at down 63%.
SURG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$3.5M |
| Q1 2026 | -$4.6M | +$2.4M |
| Q3 2025 | -$4.6M | +$8.7M |
| Q2 2025 | -$6.1M | -$2M |
| Q1 2025 | -$7M | -272% |
| Q4 2022 | $4.7M | +$12.9M |
| Q3 2022 | -$801.2K | +$1.5M |
| Q2 2022 | $175.5K | +$1.6M |
SURG has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
INTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +203M shares |
| 1 year | +17% | +776M shares |
| 3 years | +25% | +1.1B shares |
| 5 years | +30% | +1.2B shares |
| Available history | +19% | +834M shares |
INTC has the edge over SURG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | $114M |
| Q1 2021 | $2.3B |
SURG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.4% | +2.2M shares |
| 1 year | +29% | +5.9M shares |
| 3 years | +109% | +13.5M shares |
| 5 years | +1122% | +23.8M shares |
SURG has 26M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
INTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Healthy |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q1 2025 | 69.6x | High |
| Q3 2024 | 23.8x | High |
| Q2 2024 | 4.3x | High |
INTC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
SURG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -2.2x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.3x | Net Cash |
| Q2 2023 | 0.0x | Very low |
| Q1 2023 | -0.3x | Net Cash |
| Q4 2022 | 0.4x | Very low |
SURG has more cash than debt.
INTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 7.7 | Oversold |
INTC's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
SURG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 13.7 | Oversold |
SURG's weekly RSI is 32 (neutral) and its Stochastic is 14 (oversold).
INTC PE vs Technology Sector
| Metric | INTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
INTC has no meaningful PE right now: it lost money over the past year.
SURG PE vs Technology Sector
| Metric | SURG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SURG has no meaningful PE right now: it lost money over the past year.
INTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.4 | 31% below |
| 20 week MA | $95.3 | 36% below |
| 50 week MA | $79.3 | 23% below |
| 100 week MA | $52.1 | 18% above |
| 200 week MA | $42.5 | 44% above |
INTC has the edge over SURG on trend strength, trading above more of its moving averages.
SURG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.14 | 0% above |
| 20 week MA | $0.21 | 33% below |
| 50 week MA | $0.65 | 78% below |
| 100 week MA | $1.50 | 91% below |
| 200 week MA | $3.02 | 95% below |
SURG is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
INTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.1 | $47.1 | -22% |
| 2021 | $47.1 | $51.3 | +9% |
| 2022 | $51.3 | $26.1 | -49% |
| 2023 | $26.1 | $50.3 | +93% |
| 2024 | $50.3 | $20.3 | -60% |
| 2025 | $20.3 | $36.2 | +78% |
| 2026 YTD | $36.2 | $61.2 | +69% |
INTC has the edge over SURG on returns for 2026, with the stronger performance.
SURG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $6.00 | -59% |
| 2021 | $6.00 | $2.31 | -62% |
| 2022 | $2.31 | $6.29 | +172% |
| 2023 | $6.29 | $6.45 | +2.5% |
| 2024 | $6.45 | $1.83 | -72% |
| 2025 | $1.83 | $1.68 | -8.2% |
| 2026 YTD | $1.68 | $0.14 | -92% |
SURG's yearly returns have swung widely, from +172% in 2022 to −72% in 2024. It's down 92% so far in 2026.